Released Aug 13, 2024, after the close
10-Q filed Aug 13, 2024, 44 days after period end · 0001493152-24-031639
Q2 2024 · 10-Q
Revenue$47.00K$47.00K no prior Q2 2023 on file±0.0% vs Q1 2024
Net Income-$5.53M-$5.53M N/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$15.34-$15.34 N/M vs Q2 2023N/M vs Q1 2024
Gross Profit-$48,000—
Operating Income-$4,931,000N/M
Operating Cash Flowderived-$2,259,000N/M
Free Cash Flowderived-$2,508,000N/M
Margins · derived
Gross margin-102.1%
Operating margin-10491.5%
Net margin-11763.8%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $47.00K | — | — | — |
| Net Income | -$5.53M | -$4.51M | -$3.40M | -$10.09M |
| EPS Diluted | -$15.34 | -$0.85 | -$1.16 | -$0.24 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR